b-Lactam antibiotics, such as penicillins, cephalosporins and carbapenems, are the largest family of antimicrobial agents, and have been widely used in this clinical practice. 1 However, the emergence and the increased frequency of antimicrobial resistance has become a serious health problem. For this reason, the development of new antimicrobial drugs becomes a worldwide priority. Doripenem (formerly known as S-4661) is a new synthetic 1-b-methyl carbapenem antibiotic developed by Shionogi (Osaka, Japan). Doripenem is a new synthetic 1-b-methyl carbapenem antibiotic with a broad-spectrum activity against clinically pathogens including Enterobacteriaceae, nonfermenting gram-negative, anaerobes, and many gram-positive both in vivo and in vitro, including some carbapenem resistant. [2] [3] [4] [5] Recently, doripenem was indicated in the United States and Europe for the treatment of intraabdominal and complicated urinary tract infections including pyelonephritis, and approved in the Europe for patients with nosocomial pneumonia including ventilator-associated pneumonia. 4 The aim of this study is to evaluate the in vitro activity of doripenem against enterococci and E. coli isolates from wild animals, pigs, pets, poultry and humans in Portugal.
A total of 938 isolates were tested, including 522 enterococci and 416 E. coli (62 of which produced extended-spectrum b-lactamases (ESBLs)) were previously recovered from fecal samples of human and animal origin and characterized by using specific primers to species identification and detection of antibiotic resistant genes. 6 3 Moreover, the enterococci isolates from wild animals showed twofold more susceptibility to doripenem in comparison with other enterococcal origin, except in the E. faecium pets isolates, in which it showed an identical MIC 50 and MIC 90 .
The E. coli isolates were significantly more susceptible than enterococci isolates, with MIC 50 and MIC 90 values between 0.031 and 0.25 mg l À1 , respectively. The doripenem activity against E. coli was similar to that demonstrated recently by others for doripenem activity against Enterobacteriaceae, in which the overall MIC 90 values have ranged from 0.03 to 0.5 mg l À1 . 5 It is interesting to underline the relatively lower susceptibility of the human E. coli isolates to the doripenem, showing a MIC 50 and MIC 90 twofold greater than animal E. coli isolates. This lower susceptibility in human isolates can reflect the different use of antimicrobials in humans, animals, and consequently in the environment. In general, ESBL producers show lower susceptibility to the majority of the beta-lactam antibiotics than the non-producers. 5 Our study showed that ESBL-containing E. coli isolates are susceptible to doripenem with MIC 50 and MIC 90 values between 0.031 and 0.125 mg l À1 , respectively. These present data support the findings of others authors, wherein doripenem, as others carbapenems, meropenem and imipenem, remains active against ESBL-containing Enterobacteriaceae. 5, 8 In summary, although doripenem has not been effective among enterococci, our in vitro study has shown that this new antibiotic is a potent agent against E. coli, including ESBLcontaining E. coli isolates, and can be an attractive choice, alone or in combination with others antimicrobial agents, to optimize therapeutic treatment success, including infections caused by multidrug resistant strains.
